Nuvalent (NUVL) Return on Capital Employed (2021 - 2026)
Nuvalent (NUVL) reported Return on Capital Employed of 34.0% for Q1 2026, down 324.0% on a YoY basis from 15.18% in Q1 2025, and up 9.31% quarter-over-quarter from 37.49% in Q4 2025.
Nuvalent (NUVL) Return on Capital Employed (2021 - 2026) Analysis & Trends
Nuvalent has reported Return on Capital Employed for 6 years, with the latest figure at 34.0% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 324.0% year-over-year to 34.0%; the trailing twelve-month figure through Mar 2026 stood at 34.0% (down 324.0% YoY), and the FY2025 full-year result was 34.93%, down 318.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 34.0%, up from 37.49% in the prior quarter.
- The five-year high for Return on Capital Employed was 20.68% in Q1 2022, with the low at 43.25% in Q3 2025.
- Historically, Return on Capital Employed has averaged 29.42% across 5 years, with a median of 27.33% in 2023.
- Annual changes were most pronounced in 2024 — Return on Capital Employed jumped 543 bps — and 2025, when it tumbled 1595 bps.
- Nuvalent's Return on Capital Employed stood at 24.85% in 2022, then retreated by 10 bps to 27.33% in 2023, then grew by 8 bps to 25.23% in 2024, then sank by 49 bps to 37.49% in 2025, then rose by 9 bps to 34.0% in 2026.
- The last three Return on Capital Employed figures came in at 34.0% (Q1 2026), 37.49% (Q4 2025), and 43.25% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -107.40% |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -50.43% |
| 10 | Nuvalent | 9.70 Bn | 9.70 Bn | - | -34.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -34.00% |
| Dec 31, 2025 | -37.49% |
| Sep 30, 2025 | -43.25% |
| Jun 30, 2025 | -36.27% |
| Mar 31, 2025 | -30.76% |
| Dec 31, 2024 | -25.23% |
| Sep 30, 2024 | -27.30% |
| Jun 30, 2024 | -31.05% |
| Mar 31, 2024 | -25.02% |
| Dec 31, 2023 | -27.33% |
| Sep 30, 2023 | -32.73% |
| Jun 30, 2023 | -26.46% |
| Mar 31, 2023 | -21.69% |
| Dec 31, 2022 | -24.85% |
| Sep 30, 2022 | -30.49% |
| Jun 30, 2022 | -25.47% |
| Mar 31, 2022 | -20.68% |
| Dec 31, 2021 | -15.68% |
| Sep 30, 2021 | -15.37% |